Dr. Reddy’s Laboratories (NYSE:RDY) Sets New 52-Week Low – Time to Sell?

Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $13.61 and last traded at $13.68, with a volume of 957993 shares. The stock had previously closed at $14.01.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RDY shares. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Barclays decreased their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Finally, StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Performance

The firm has a market cap of $11.37 billion, a price-to-earnings ratio of 21.80 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. The firm’s 50 day moving average is $14.86 and its 200-day moving average is $15.52.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%. Sell-side analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.81 earnings per share for the current fiscal year.

Institutional Trading of Dr. Reddy’s Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Robeco Institutional Asset Management B.V. increased its stake in Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the period. State Street Corp increased its stake in Dr. Reddy’s Laboratories by 1.9% in the third quarter. State Street Corp now owns 909,905 shares of the company’s stock valued at $72,292,000 after acquiring an additional 16,641 shares during the period. Fisher Asset Management LLC increased its stake in Dr. Reddy’s Laboratories by 59.4% in the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after acquiring an additional 183,146 shares during the period. BNP Paribas Financial Markets increased its stake in Dr. Reddy’s Laboratories by 30.8% in the third quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock valued at $32,530,000 after acquiring an additional 96,339 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its stake in Dr. Reddy’s Laboratories by 318.0% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock valued at $28,411,000 after acquiring an additional 283,700 shares during the period. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.